Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Pittsburgh, Pennsylvania

Cancer surgery and procedure trials in Pittsburgh, PA

55 cancer surgery and procedure studies are recruiting participants at sites in Pittsburgh as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Pittsburgh at a glance

  • 55 studies are recruiting at a site in Pittsburgh.
  • By phase: Phase 1 (4), Phase 1/2 (8), Phase 2 (19), Phase 2/3 (1), Phase 3 (17), No phase (2), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (32), government (22), industry (1).
  • By research area: Lymphoma (17), Lung Cancer (13), Breast Cancer (8), Prostate Cancer (7), Melanoma (5), Pancreatic Cancer (5).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Pittsburgh

Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT03606967 · updated
  2. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05372640 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT05564377 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
    Registry record
    NCT06058377 · updated
  5. Distance-Based Exercise to Preserve Function and Prevent Disability

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT07059884 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lung cancer studies recruiting in Pittsburgh

  1. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT04665739 · updated
  2. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06498635 · updated
  3. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Texas Southwestern Medical Center
    Study site
    Allegheny
    Registry record
    NCT02468024 · updated
  4. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06287775 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Mercy Hospital · UPMC-Passavant Hospital
    Registry record
    NCT04267848 · updated
  6. Detection of Genetic Markers of Lung Cancer

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Pittsburgh
    Study site
    Hillman Cancer Center
    Registry record
    NCT00280202 · updated
  7. A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Clair Hospital Cancer Center
    Registry record
    NCT07293247 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Pittsburgh

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Clair Hospital Cancer Center
    Registry record
    NCT03866382 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT04423211 · updated
  3. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Allegheny General Hospital · West Penn Hospital
    Registry record
    NCT06931340 · updated
  4. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT05946213 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Melanoma studies recruiting in Pittsburgh

  1. Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07040280 · updated
  2. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lymphoma studies recruiting in Pittsburgh

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT06317662 · updated
  2. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT04726241 · updated
  3. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT04546399 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT05675410 · updated
  5. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07003295 · updated
  6. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Shadyside Hospital
    Registry record
    NCT07215910 · updated
  7. Collection of Tissue Samples for Cancer Research

    • Observational
    • From 2 months
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT00900198 · updated
  8. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT06124157 · updated
  9. Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06860594 · updated
  10. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    • Phase 2
    • Ages 1 to 60
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    University of Pittsburgh Cancer Institute (UPCI)
    Registry record
    NCT03970096 · updated
  11. Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07332507 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Pittsburgh

  1. Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07619521 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Ask about studies near Pittsburgh

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call